Back to School: How biopharma can reboot drug development. Access exclusive analysis here

TMC435350: Phase IIa started

JNJ's Tibotec unit began a double-blind, European Phase IIa trial (TMC435350-C201) in 120

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE